by Nicolas Hulscher, MPH

Today, Pfizer announced a "landmark agreement" with the Trump Administration. The press release promised lower drug costs and a revival of U.S. manufacturing. President Donald Trump touted that Pfizer would cut Medicaid drug prices for low-income Americans and sell new medicines at a "most-favored-nation" price — but only in exchange for tariff relief.

In reality, it appears to be a multi-billion dollar effort to entrench Pfizer's failed gene-transfer platforms for decades to come.